logo
Plus   Neg
Share
Email

Novartis Reports Post Hoc Analysis From Phase III IRIDIUM Study

Novartis (NVS) presented post hoc analysis from the pivotal Phase III IRIDIUM study, which showed that high-dose, once-daily Enerzair Breezhaler significantly reduced both moderate-or-severe and severe asthma exacerbation rates in patients whose asthma is uncontrolled on medium- or high-dose long-acting beta2-agonist/inhaled corticosteroids, when compared with a once-daily medium-dose of the same treatment. The study also showed the safety profile for high-dose Enerzair Breezhaler was in line with previous studies in the Phase III/IIIb PLATINUM clinical development program.

IRIDIUM was a phase III, multicenter, randomized, double-blind, parallel-group study, designed to compare the efficacy and safety of IND/GLY/MF with IND/MF in patients with asthma.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Orca Bay Foods, LLC recalled about 4,450 pounds of Trader Joe's brand Gluten Free Battered Halibut products for undeclared wheat and milk allergens, according to a statement published by the U.S. Food and Drug Administration (FDA). The action was initiated after it was discovered that product containing Wheat and Milk was distributed in packaging. Lee Kun-hee, the Chairman of South Korean conglomerate Samsung Group, has died on October 25, at the age of 78. It was he who transformed Samsung into a South Korean behemoth, and the world's largest manufacturer of smartphones, televisions, and semiconductors. As per reports, Lee's only son Jae-yong, who currently serves as vice chairman of Samsung Electronics, is likely to take over Samsung. Toy and board game company Hasbro, Inc. (HAS) reported Monday net earnings attributable to Hasbro for the third quarter of $220.90 million or $1.61 per share, compared to pro forma net earnings of $216.5 million or $1.57 per share in the year-ago period. Excluding items, adjusted earnings for the...
Follow RTT